Accelerating to Zero: Targeting Roadblocks to Achieve Malaria Elimination

A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria

DH Opi, RJ Longley, E Takashima, T Spelman, Y Tayipto, K Schoffer, J Brewster, L Reiling, BD Wines, B Kiniboro, P Siba, M Harbers, M Hogarth, T Tsuboi, LJ Robinson, I Mueller, JG Beeson

2026-03-10

Understanding immunity against Plasmodium vivax, a leading cause of malaria, will accelerate development of vaccines, which are cu..

The role of the spleen in red blood cell loss caused by malaria: A mathematical model

R Moss, S Dini, S Kho, BE Barber, PA Buffet, M Rajasekhar, DJ Price, NM Anstey, JA Simpson

2026-01-12

The human spleen significantly influences red blood cell (RBC) dynamics due to its ability to retain and/or remove RBCs from perip..

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

TS Degaga, AP Pasaribu, R Tripura, N Ghanchi, M Rajasekhar, B Adhikari, B Ley, SA Bamboro, FA Jabbar, N Hasibuan, TT Tego, S Zehra, B Qurashi, H Mnjala, G Lee, P Li, AM Kazi, W Safitri, Y Yulita, DSP Siagian

2026-01-01

Background: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmo..

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches

MK Tully, RJ Commons, JA Simpson, DJ Price

2026-01-01

In silico pharmacokinetic–pharmacodynamic (PK–PD) models are used to inform dose optimisation in antimalarial drug development. He..

How to use learning curves to evaluate the sample size for malaria prediction models developed using machine learning algorithms

SG Zaloumis, M Rajasekhar, JA Simpson

2025-12-01

Background: Machine learning algorithms have been used to predict malaria risk and severity, identify immunity biomarkers for mala..

Systematic review and individual patient data meta-analysis on glucose- 6 – phosphate dehydrogenase activities measured by a semi-quantitative handheld biosensor

B Ley, LR Vasquez, A Sitsabasan, B Adhikari, N Adhikari, MS Alam, S Das, P Ghimire, MVG Lacerda, RN Price, KR Rijal, L von Seidlein, A Talukdar, K Thriemer, AW Satyagraha, A Sadhewa, M Rajasekhar, RJ Commons

2025-12-01

Background: Measurement of glucose-6-phosphate dehydrogenase (G6PD) activity guides hypnozoitocidal treatment of P vivax malaria. ..

Navigating parasite antigen genetic diversity in the design of Plasmodium vivax serological exposure markers for malaria.

Paolo Bareng, Kenneth W Wu, Eizo Takashima, Dionne Argyropoulos, Lauren Smith, Myo Naung, Ramin Mazhari, Kael Schoffer, Nicholas Kiernan-Walker, Anju Abraham, Macie Lamont, Somya Mehra, Pailene Lim, Jetsumon Sattabongkot, Wuelton Monteiro, Marcus Lacerda, Julie Healer, Chetan E Chitnis, Wai-Hong Tham, Takafumi Tsuboi

2025-07-08

BACKGROUND: Plasmodium vivax poses a major obstacle to malaria elimination because it can lie dormant in the liver for weeks or mo..

Human antibodies against Anopheles salivary proteins: emerging biomarkers of mosquito and malaria exposure

EA Kearney, AS Heng-Chin, K O'Flaherty, FJI Fowkes

2025-05-01

Antibodies developed against Anopheles mosquito salivary proteins injected during biting may serve as proxy biomarkers of Anophele..

Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

JA Watson, P Mehdipour, R Moss, P Jittamala, S Zaloumis, DJ Price, S Dini, B Hanboonkunupakarn, P Leungsinsiri, K Poovorawan, K Chotivanich, G Bancone, RJ Commons, NPJ Day, S Pukrittayakamee, WRJ Taylor, NJ White, JA Simpson

2025-04-01

Primaquine is the only widely available drug to prevent relapses of Plasmodium vivax malaria. Primaquine is underused because of c..

Evaluation of a Bayesian hierarchical pharmacokinetic–pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs

MK Tully, S Dini, JA Flegg, JS McCarthy, DJ Price, JA Simpson

2024-09-01

The rise of multidrug-resistant malaria requires accelerated development of novel antimalarial drugs. Pharmacokinetic–pharmacodyna..

Geospatial joint modeling of vector and parasite serology to microstratify malaria transmission

EA Kearney, P Amratia, SY Kang, PA Agius, KA Alene, K O’Flaherty, WH Oo, JC Cutts, W Htike, D Da Silva Goncalves, Z Razook, AE Barry, D Drew, A Thi, KZ Aung, HK Thu, MM Thein, NN Zaw, WYM Htay, AP Soe

2024-06-11

The World Health Organization identifies a strong surveillance system for malaria and its mosquito vector as an essential pillar o..